NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

EyePoint (EYPT) Is Up 25.0% After DURAVYU Phase 3 Safety Green Light And $200M ATM Offering

EyePoint, Inc. (formerly EyePoint Pharmaceuticals, Inc.) recently secured a positive safety recommendation to continue its Phase 3 DURAVYU trials and filed a prospectus supplement for a Controlled Equity Offering of up to US$200,000,000 in common stock, while a major insider modestly reduced her holdings. The combination of a clean safety review for DURAVYU and a sizable at-the-market equity program highlights both the company’s clinical momentum and its need to fund a capital-intensive...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

Expedia (EXPE): Assessing the Valuation After New Set Jetting Hub Launch and AI Leadership Appointment

Expedia Group (EXPE) just doubled down on two big themes driving its business by launching a Set Jetting travel hub for screen inspired trips and appointing its first chief AI and data officer. See our latest analysis for Expedia Group. Those moves come as momentum builds in the stock, with a 21.46% 3 month share price return and a 42.67% year to date share price return contributing to a 178.81% 3 year total shareholder return. If this kind of thematic growth story appeals to you, it could be...
NasdaqGM:APPN
NasdaqGM:APPNSoftware

Appian (APPN): Valuation Check After Healthcare AI Workflow Win at HL7 AI Challenge

Appian (APPN) just picked up global recognition in healthcare tech, with its joint “Bring AI to Work(flow)” solution winning the HL7 AI Challenge for interoperable and ethical AI driven workflows in patient care. See our latest analysis for Appian. That backdrop of validation seems to be feeding into sentiment, with a 90 day share price return of 31.54 percent pushing Appian to 29.68 percent year to date. However, the five year total shareholder return remains sharply negative and reminds...
NasdaqGS:NBIS
NasdaqGS:NBISSoftware

Nebius Group (NBIS): Valuation Check After Major Microsoft and Meta AI Infrastructure Deals

Nebius Group (NBIS) just locked in multi billion dollar AI infrastructure deals with Microsoft and Meta, but the stock is wobbling as investors weigh that growth story against rising debt and a stretched valuation. See our latest analysis for Nebius Group. Those mega deals arrive after a wild run, with Nebius delivering a soaring year to date share price return of 228.84 percent but cooling off with a 30 day share price return of negative 9.84 percent, suggesting momentum is pausing rather...
NYSE:STT
NYSE:STTCapital Markets

State Street (STT): Reviewing Valuation After This Year’s 27% Share Price Gain

State Street (STT) has quietly ground out steady gains this year, and its recent move higher is catching more investor attention. With the stock up roughly 27% year to date, the question is whether that momentum still looks reasonable. See our latest analysis for State Street. The steady climb in State Street’s share price to about $124, alongside a 12.0% 3 month share price return and a 27.9% 1 year total shareholder return, suggests momentum is still building rather than fading. If you are...
NYSE:AMP
NYSE:AMPCapital Markets

Should Ameriprise’s (AMP) Harpland Acquisition Shape How Investors View Its Adviser Growth Strategy?

In November 2025, Ameriprise Financial announced that Houston-based Harpland Financial Management joined its branch channel from Wells Fargo Clearing Services with more than US$160 million in client assets, bringing advisors Peter Horton and Serena Sneeringer and client service associate Micah Horton onto its platform. This move underscores growing adviser interest in Ameriprise’s technology, integrated planning tools, and service support at a time when the firm’s earnings per share,...
NasdaqGS:FISV
NasdaqGS:FISVDiversified Financial

Fiserv (FISV) Valuation Check After Prolonged Share Price Decline and Recent Short-Term Rebound

Fiserv (FISV) has had a rough stretch, with the stock down about 68% over the past year even as the underlying business keeps grinding out modest revenue and profit growth. Investors are wondering what they are missing. See our latest analysis for Fiserv. The latest leg lower leaves Fiserv trading at $65.73, and while the 7 day share price return of 4.85% hints at a tentative bounce, the 1 year total shareholder return of negative 67.60% and 5 year total shareholder return of negative 42.15%...